These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 15818335

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis.
    Sellers MT, McGuire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE.
    Transplantation; 2004 Oct 27; 78(8):1212-7. PubMed ID: 15502722
    [Abstract] [Full Text] [Related]

  • 23. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL, Ramos E, Lin A, Vincenti F, Daclizumab Triple Therapy and Double Therapy Groups.
    Transplantation; 2001 Aug 27; 72(4):642-7. PubMed ID: 11544424
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients.
    Niemeyer G, Koch M, Light S, Kuse ER, Nashan B.
    Am J Transplant; 2002 May 27; 2(5):454-60. PubMed ID: 12123212
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients.
    Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS.
    Transplantation; 2000 May 15; 69(9):1867-72. PubMed ID: 10830224
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab).
    Sloand EM, Scheinberg P, Maciejewski J, Young NS.
    Ann Intern Med; 2006 Feb 07; 144(3):181-5. PubMed ID: 16461962
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.